URGN
Income statement / Annual
Last year (2025), UroGen Pharma Ltd's total revenue was $109.79 M,
an increase of 21.45% from the previous year.
In 2025, UroGen Pharma Ltd's net income was -$153.49 M.
See UroGen Pharma Ltd,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$109.79 M |
$90.40 M |
$82.71 M |
$64.36 M |
$48.04 M |
$11.80 M |
$18.00 K |
$1.13 M |
$8.16 M |
$17.53 M |
| Cost of Revenue |
$12.45 M
|
$8.88 M
|
$9.36 M
|
$7.65 M
|
$5.16 M
|
$1.01 M
|
$0.00
|
$1.80 M
|
$600.00 K
|
$28.00 K
|
| Gross Profit |
$97.34 M
|
$81.52 M
|
$73.35 M
|
$56.70 M
|
$42.89 M
|
$10.79 M
|
$18.00 K
|
-$675.00 K
|
$7.56 M
|
$17.50 M
|
| Gross Profit Ratio |
0.89
|
0.9
|
0.89
|
0.88
|
0.89
|
0.91
|
1
|
-0.6
|
0.93
|
1
|
| Research and Development Expenses |
$67.11 M
|
$57.15 M
|
$45.61 M
|
$52.91 M
|
$47.64 M
|
$47.31 M
|
$49.30 M
|
$36.93 M
|
$18.70 M
|
$10.29 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$60.20 M
|
$39.57 M
|
$8.81 M
|
$6.42 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$155.10 M
|
$0.00
|
$93.27 M
|
$82.84 M
|
$0.00
|
$90.22 M
|
$60.20 M
|
$39.57 M
|
$8.81 M
|
$6.42 M
|
| Other Expenses |
$0.00
|
$121.15 M
|
$0.00
|
$0.00
|
$87.54 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$222.20 M
|
$178.30 M
|
$138.89 M
|
$135.74 M
|
$135.18 M
|
$137.53 M
|
$109.50 M
|
$76.51 M
|
$27.51 M
|
$16.70 M
|
| Cost And Expenses |
$234.65 M
|
$187.18 M
|
$148.25 M
|
$143.40 M
|
$140.33 M
|
$138.54 M
|
$109.50 M
|
$78.31 M
|
$28.11 M
|
$16.73 M
|
| Interest Income |
$5.97 M
|
$8.90 M
|
$2.64 M
|
$938.00 K
|
$365.00 K
|
$1.99 M
|
$4.62 M
|
$1.87 M
|
$125.00 K
|
$1.00 K
|
| Interest Expense |
$33.85 M
|
$12.52 M
|
$14.72 M
|
$8.44 M
|
$0.00
|
$357.00 K
|
$284.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$2.41 M
|
$329.00 K
|
$1.71 M
|
$1.82 M
|
$831.00 K
|
$2.04 M
|
$1.32 M
|
$417.00 K
|
$207.00 K
|
$213.00 K
|
| EBITDA |
-$135.66 M |
-$95.35 M |
-$60.35 M |
-$76.21 M |
-$91.46 M |
-$122.71 M |
-$108.15 M |
-$77.18 M |
-$19.74 M |
$1.01 M |
| EBITDA Ratio |
-1.24
|
-1.05
|
-0.73
|
-1.18
|
-1.9
|
-10.4
|
-6008.56
|
-68.42
|
-2.42
|
0.06
|
| Operating Income Ratio |
-1.14
|
-1.07
|
-0.79
|
-1.23
|
-1.92
|
-10.74
|
-6082.11
|
-68.42
|
-2.45
|
0.05
|
| Total Other Income/Expenses Net |
-$28.55 M
|
-$27.26 M
|
-$32.79 M
|
-$28.99 M
|
-$17.08 M
|
$1.63 M
|
$4.33 M
|
$1.65 M
|
-$31.00 K
|
-$2.74 M
|
| Income Before Tax |
-$153.42 M
|
-$124.04 M
|
-$98.32 M
|
-$108.03 M
|
-$109.37 M
|
-$125.11 M
|
-$105.15 M
|
-$75.53 M
|
-$19.98 M
|
-$1.94 M
|
| Income Before Tax Ratio |
-1.4
|
-1.37
|
-1.19
|
-1.68
|
-2.28
|
-10.6
|
-5841.44
|
-66.96
|
-2.45
|
-0.11
|
| Income Tax Expense |
$78.00 K
|
$2.83 M
|
$3.92 M
|
$1.76 M
|
$1.45 M
|
$3.37 M
|
$0.00
|
$125.00 K
|
$19.00 K
|
$0.00
|
| Net Income |
-$153.49 M
|
-$126.87 M
|
-$102.24 M
|
-$109.78 M
|
-$110.82 M
|
-$128.48 M
|
-$105.15 M
|
-$75.66 M
|
-$20.00 M
|
-$1.94 M
|
| Net Income Ratio |
-1.4
|
-1.4
|
-1.24
|
-1.71
|
-2.31
|
-10.89
|
-5841.44
|
-67.07
|
-2.45
|
-0.11
|
| EPS |
-3.19 |
-2.96 |
-3.55 |
-4.79 |
-4.96 |
-5.9 |
-4.9 |
-4.8 |
-2.06 |
-0.16 |
| EPS Diluted |
-3.19 |
-2.96 |
-3.55 |
-4.79 |
-4.96 |
-5.9 |
-4.9 |
-4.8 |
-2.06 |
-0.16 |
| Weighted Average Shares Out |
$48.12 M
|
$42.88 M
|
$28.83 M
|
$22.81 M
|
$22.35 M
|
$21.78 M
|
$20.53 M
|
$15.75 M
|
$9.72 M
|
$11.97 M
|
| Weighted Average Shares Out Diluted |
$48.12 M
|
$42.88 M
|
$28.83 M
|
$22.81 M
|
$22.35 M
|
$21.78 M
|
$20.53 M
|
$15.75 M
|
$9.72 M
|
$11.97 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
